Ryan Deschner
Stock Analyst at Raymond James
(4.76)
# 116
Out of 4,935 analysts
16
Total ratings
86.67%
Success rate
34.98%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ryan Deschner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TRVI Trevi Therapeutics | Maintains: Strong Buy | $29 → $27 | $7.42 | +263.88% | 3 | Aug 8, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Outperform | $54 | $41.00 | +31.71% | 1 | Aug 6, 2025 | |
| ARDX Ardelyx | Maintains: Outperform | $11 → $12 | $5.21 | +130.33% | 2 | Aug 5, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $52 → $50 | $24.38 | +105.13% | 2 | Aug 1, 2025 | |
| VKTX Viking Therapeutics | Maintains: Strong Buy | $125 → $122 | $37.89 | +221.98% | 1 | Jul 24, 2025 | |
| TVRD Tvardi Therapeutics | Initiates: Outperform | $62 | $23.93 | +159.14% | 1 | Jul 14, 2025 | |
| LQDA Liquidia | Maintains: Strong Buy | $27 → $29 | $20.45 | +41.81% | 3 | May 9, 2025 | |
| SPRY ARS Pharmaceuticals | Maintains: Strong Buy | $26 → $28 | $17.50 | +60.00% | 3 | Jan 14, 2025 |
Trevi Therapeutics
Aug 8, 2025
Maintains: Strong Buy
Price Target: $29 → $27
Current: $7.42
Upside: +263.88%
Palvella Therapeutics
Aug 6, 2025
Initiates: Outperform
Price Target: $54
Current: $41.00
Upside: +31.71%
Ardelyx
Aug 5, 2025
Maintains: Outperform
Price Target: $11 → $12
Current: $5.21
Upside: +130.33%
Apellis Pharmaceuticals
Aug 1, 2025
Maintains: Outperform
Price Target: $52 → $50
Current: $24.38
Upside: +105.13%
Viking Therapeutics
Jul 24, 2025
Maintains: Strong Buy
Price Target: $125 → $122
Current: $37.89
Upside: +221.98%
Tvardi Therapeutics
Jul 14, 2025
Initiates: Outperform
Price Target: $62
Current: $23.93
Upside: +159.14%
Liquidia
May 9, 2025
Maintains: Strong Buy
Price Target: $27 → $29
Current: $20.45
Upside: +41.81%
ARS Pharmaceuticals
Jan 14, 2025
Maintains: Strong Buy
Price Target: $26 → $28
Current: $17.50
Upside: +60.00%